Loading...
Loading...
Below are the top drugs-generic stocks on the NASDAQ in terms of EPS growth forecast for the next five years.
Evoke Pharma IncEVOK earnings per share growth forecast for the next five years is 40.00 percent. Evoke Pharma has a market capitalization of $33.54 million.
Steadymed Ltd STDY EPS growth forecast for the next five years is 37.50 percent. Steadymed's trailing-twelve-month EPS is -$1.78.
Sagent Pharmaceuticals Inc SGNT EPS growth forecast for the next five years is 26.68 percent. Sagent Pharmaceuticals' PEG ratio is 0.91.
Akorn, Inc.AKRX earnings per share growth forecast for the next five years is 23.72 percent. Akorn's trailing-twelve-month ROE is 11.10 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in